Skip to main content

Advertisement

  • Correction
  • Open Access

Correction to: AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial

  • 1, 2Email author,
  • 1, 2,
  • 3,
  • 4,
  • 5,
  • 6, 7,
  • 4,
  • 8,
  • 4,
  • 9,
  • 10,
  • 11,
  • 11,
  • 4,
  • 3,
  • 6,
  • 2, 12,
  • 6,
  • 5, 8,
  • 9,
  • 8,
  • 13,
  • 5, 10,
  • 8,
  • 8,
  • 13,
  • 8,
  • 3 and
  • 1, 2
Trials201920:48

https://doi.org/10.1186/s13063-018-3155-9

  • Received: 28 December 2018
  • Accepted: 28 December 2018
  • Published:

The original article was published in Trials 2018 19:649

Correction to: Trials (2018) 19:649

https://doi.org/10.1186/s13063-018-3026-4

Following publication of the original article [1], we have been notified that one of the author names was listed incorrectly. Both incorrect and correct author names are presented below. The original publication has been corrected.
  • Originally published name:

    Sile L F Molloy

  • Correct name:

    Sile F Molloy

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK
(2)
Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana
(3)
Research Centre for Infection and Immunity, St George’s University of London, London, UK
(4)
Molecular Mycology Unit and National Reference Centre for Invasive Mycoses, Institut Pasteur, Paris, France
(5)
Malawi-Liverpool-Wellcome Trust Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi
(6)
Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda
(7)
Department of Medicine, University of Minnesota, Minneapolis, MN, USA
(8)
Department of Clinical Sciences and International Public Health, Liverpool School of Tropical Medicine, Liverpool, UK
(9)
Department of Medicine, University of Zimbabwe College of Health Sciences, Parirenyatwa Hospital, Harare, Zimbabwe
(10)
Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK
(11)
Lilongwe Medical Relief Trust (UNC Project), Lilongwe, Malawi
(12)
Department of Internal Medicine, University of Botswana, Gaborone, Botswana
(13)
Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine, and Department of Medicine, University of Cape Town, Cape Town, South Africa

Reference

  1. Lawrence DS, et al. AMBIsome Therapy Induction OptimisatioN (AMBITION): High Dose AmBisome for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: Study Protocol for a Phase 3 Randomised Controlled Non-Inferiority Trial. Trials. 2018;19:649. https://doi.org/10.1186/s13063-018-3026-4.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2019

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.

Advertisement